Identification of a novel in-frame deletion in BRCA2 and analysis of variants of BRCA1/2 in Italian patients affected with hereditary breast and ovarian cancer

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 12, 2012, Pages 2171-2180

  Vietri, Maria Teresa ^a   Molinari, Anna Maria ^a   De Paola, Maria Laura ^a   Cantile, Flavia ^a   Fasano, Morena ^a   Cioffi, Michele ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Dpt Biol e Patol Cell e Molecol   (Italy)

Author keywords

BRCA1; BRCA2; Breast cancer; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; MESSENGER RNA;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; EXON; FAMILIAL CANCER; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; GENE IDENTIFICATION; GENE LOSS; GENE MUTATION; GENE REARRANGEMENT; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; INTRON; ITALY; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; OVARY CANCER; POINT MUTATION; PRIORITY JOURNAL; RNA ANALYSIS;

BASE SEQUENCE; BREAST NEOPLASMS; DNA PRIMERS; FEMALE; GENE DELETION; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ITALY; MUTATION; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84872870147     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0154     Document Type: Article

References (42)

1. Palma M, Ristori E, Ricevuto E, Giannini G, Gulino A. BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers. Crit Rev Oncol Hematol 2006;57:1-23.
2. Campeau PM, Foulkes WD, Tischkowitz MD. Hereditary breast cancer: new genetic developments, therapeutic avenues. Hum Genet 2008;124:31-42.
3. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. J Am Med Assoc 2006;295:1379-88.
4. McInerney NM, Miller N, Rowan A, Colleran G, Barclay E, Curran C, et al. Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort. Breast Cancer Res Treat 2010;121:203-10.
5. Park DJ, Lesueur F, Nguyen-Dumont T, Pertesi M, Odefrey F, Hammet SL, et al. Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet 2012;90:734-9.
6. Goldberg JI, Borgen PI. Breast cancer susceptibility testing: past, present and future. Expert Rev Anticancer Ther 2006;6:1205-14.
7. Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007;7:937-48.
8. Tommasi S, Crapolicchio A, Lacalamita R, Bruno M, Monaco A, Petroni S, et al. BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy. Mutat Res 2005;578:395-405.
9. Ottini L, Masala G, D'Amico C, Mancini B, Saieva C, Aceto G, et al. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res 2003;63:342-7.
10. Casilli F, Tournier I, Sinilnikova OM, Coulet F, Soubrier F, Houdayer C, et al. The contribution of germline rearrangements to the spectrum of BRCA2 mutations. J Med Genet 2006;43:e49.
11. Buffone A, Capalbo C, Ricevuto E, Sidoni T, Ottini L, Falchetti M, et al. Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families. Breast Cancer Res Treat 2007;106:289-96.
12. Lee E, McKean-Cowdin R, Ma H, Chen Z, Van Den Berg D, Henderson BE, et al. Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods: results from a population-based study of young breast cancer patients. Breast Cancer Res 2008;10:R19.
13. World Medical Association (WMA). The WMA declaration of Helsinki 1960 with recommendations on biomedical research on human subjects (modified in 1975, 1980 and 1989). Chirurgia (Bucur) 1998;93:138-40.
14. Wagner T, Stoppa-Lyonnet D, Fleischmann E, Muhr D, Pages S, Sandberg T, et al. Denaturing high-performance liquid chromatography detect reliably BRCA1 and BRCA2 mutations. Genomics 1999;62:369-76.
15. Wagner T, Hirtenlehner K, Shen P, Moeslinger R, Muhr D, Fleischmann E, et al. Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations. Hum Mol Genet 1999;8:413-23.
16. den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000;15:7-12.
17. Gutierrez-Enriquez S, Balmana J, Baiget M, Diez O. Detection of the CHECK2 1100delC mutation by MLPA BRCA1/2 analysis: a worthwhile strategy for its clinical application in 1100delC low-frequency populations? Breast Cancer Res Treat 2008;107:455-7.
18. Stuppia L, Di Fulvio P, Aceto G, Pintor S, Veschi S, Gatta V, et al. BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy. Hum Mutat 2003;22:178-9.
19. Caligo MA, Bonatti F, Guidugli L, Aretini P, Galli A. A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance. Hum Mutat 2009;30:123-33.
20. Ellisen LW, Haber DA. Hereditary breast cancer. Annu Rev Med 1998;49:425-36.
21. Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations: risk factor analysis and implications for genetic testing. J Am Med Assoc 1997;278:1242-50.
22. Spain BH, Larson CJ, Shihabuddin LS, Gage FH, Verma IM. Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations. Proc Natl Acad Sci USA 1999;96:13920-5.
23. Martinez SL, Herzog J, Weitzel JN. Loss of five amino acids in BRCA2 is associated with ovarian cancer. J Med Genet 2004;41:e18.
24. Kim BY, Lee DG, Lee KR, Han SH, Surendran S, Han CW, et al. Identification of BRCA1 and BRCA2 mutations from Korean breast cancer patients using denaturing HPLC. Biochem Biophys Res Commun 2006;349:604-10.
25. Demange L, Noguchi T, Sauvan R, Moyal-Amsellem N, Birnbaum D, Eisinger F, et al. A novel germline in-frame deletion (4128del3) of the BRCA2 gene detected in a breast/ovarian cancer family with fallopian tube and brain tumors identified in the north of France. Hum Mutat 2001;17:155.
26. Patmasiriwat P, Bhothisuwan K, Sinilnikova OM, Chopin S, Methakijcaroon S, Badzioch M, et al. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer. Hum Mutat 2002;20:230.
27. Thompson D, Easton D. Breast Cancer Linkage Consortium. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410-9.
28. Shivji MK, Davies OR, Savill JM, Bates DL, Pellegrini L, Venkitaraman AR. A region of human BRCA2 containing multiple BRC repeats promotes RAD51-mediated strand exchange. Nucleic Acids Res 2006;34:4000-11.
29. Chen CF, Chen PL, Zhong Q, Sharp ZD, Lee WH. Expression of BRC repeats in breast cancer cells disrupts the BRCA2-Rad51 complex and leads to radiation hypersensitivity and loss of G(2)/M checkpoint control. J Biol Chem 1999;274:32931-5.
30. Wong AK, Pero R, Ormonde PA, Tavtigian SV, Bartel PL. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene BRCA2. J Biol Chem 1997;272:31941-4.
31. Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. Breast Cancer Information Core (BIC) Steering Committee. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 2004;75:535-44.
32. Chenevix-Trench G, Healey S, Lakhani S, Waring P, Cummings M, Brinkworth R, et al. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 2006;66:2019-27.
33. Borg A, Haile RW, Malone KE, Capanu M, Diep A, Törngren T, et al. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat 2010;31:E1200-40.
34. Caldes T, de la Hoya M, Tosar A, Suelliro S, Godin J, Ibanez D, et al. A breast cancer family form Spain with germline mutations in both the BRCA1 and BRCA2 genes. J Med Genet 2002;38:e44.
35. Durocher F, Shattuck-Eidens D, McClure M, Labrie F, Skolnick MH, Goldgar DE, et al. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet 1996;5:835-42.
36. Takahashi H, Behbakht K, McGovern PE, Chiu HC, Couch FJ, Weber BL, et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 1995;55:2998-3002.
37. Osorio A, de la Hoya M, Rodriguez-Lopez R, Martinez-Ramirez A, Cazorla A, Granizo JJ, et al. Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int J Cancer 2002;99:305-9.
38. Dosil V, Tosar A, Canadas C, Perz-Segura P, Diaz-Rubio E, Caldes T, et al. Alternative splicing and molecular characterization of splice site variants: BRCA1 c.591C T as a case study. Clin Chem 2010;56:53-61.
39. Lixia M, Zhijian C, Chao S, Chaojiang G, Congyi Z. Alternative splicing of breast cancer associated gene BRCA1 from breast cancer cell line. J Biochem Mol Biol 2007;40:15-21.
40. Orban TI, Olah E. Emerging roles of BRCA1 alternative splicing. Mol Pathol 2003;56:191-7.
41. Bièche I, Lidereau R. Increased level of exon 12 alternatively spliced BRCA2 transcripts in tumor breast tissue compared with normal tissue. Cancer Res 1999;59:2546-50.
42. Nathanson KL, Weber B. Other breast cancer susceptibility genes: searching for more holy grail. Hum Mol Genet 2001;10: 715-20.